We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current AKTX market cap is 27.25M. The company's latest EPS is USD -1.0240 and P/E is -2.23.
Quarter End | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Operating Income | -4.33M | -1.46M | -5.9M | -5.24M | -5.82M |
Net Income | -4.35M | -1.45M | -5.79M | -5.18M | -5.68M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 199k | 556k | 0 | 0 | 330k |
Operating Income | -16.78M | -17.45M | -17.24M | -25.4M | -19.73M |
Net Income | -16.85M | -17.08M | -17.42M | -17.01M | -12.24M |
Quarter End | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 4.83M | 14.72M | 11.65M | 19.46M | 11.37M |
Total Liabilities | 3.24M | 3.36M | 6.09M | 5.52M | 3.05M |
Total Equity | 1.59M | 11.36M | 5.56M | 13.93M | 8.33M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 6.48M | 14.61M | 11.65M | 16.22M | 5.57M |
Total Liabilities | 6.47M | 5.22M | 6.09M | 10.98M | 4.58M |
Total Equity | 8k | 9.38M | 5.56M | 5.24M | 988k |
Quarter End | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -12.28M | -13.84M | N/A | -5.05M | -13.62M |
Investing | N/A | N/A | N/A | N/A | N/A |
Financing | 1.99M | 13.18M | N/A | 12.37M | 12.37M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -12.92M | -16.95M | -18.85M | -21.5M | -16.38M |
Investing | N/A | N/A | N/A | N/A | N/A |
Financing | 12.65M | 25.07M | 14.29M | 25.29M | 6.97M |
Market Cap | 27.25M |
Price to Earnings Ratio | -2.23 |
Price to Sales Ratio | 82.61 |
Price to Cash Ratio | 7.09 |
Price to Book Ratio | 27.58 |
Dividend Yield | - |
Shares Outstanding | 11.95M |
Average Volume (1 week) | 0 |
Average Volume (1 Month) | 0 |
52 Week Change | - |
52 Week High | - |
52 Week Low | - |
Spread (Intraday) | 0.07 (3.02%) |
Company Name | Akari Therapeutics PLC |
Address |
highdown house yeoman west sussex BN99 3HH |
Website | https://www.akaritx.com |
Industry | coml physical, biologcl resh (8731) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions